{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:02:59Z","timestamp":1784739779821,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To identify which patients with pulmonary aspergillosis or mucormycosis (PAM) derive the greatest incremental diagnostic benefit from next-generation sequencing (NGS) beyond conventional microbiology, and to derive a GM \u00d7 NGS interpretive framework that identifies the patient subgroup in which NGS adds the most information, based on routinely available bedside variables. Secondary objectives were to characterize the pathogen spectrum detected by NGS, quantify pairwise concordance with BALF galactomannan and culture, and assess the relationship between quantitative Aspergillus reads and BALF-GM intensity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Two-center retrospective case-cohort study of 595 adults with NGS-tested pulmonary aspergillosis or mucormycosis (PAM; proven, probable, or possible per EORTC\/MSGERC and ECMM-MSGERC criteria). Primary method-comparison analysis was restricted to the strict subset with NGS, BALF-galactomannan (GM), and culture all available (\n                      <jats:italic>n<\/jats:italic>\n                      = 434). Total Aspergillus reads were defined as the per-case sum of species-level Aspergillus reads parsed from free-text NGS reports, with Mucorales reads excluded. Multivariable logistic regression identified predictors of GM-negative status among NGS-positive cases (\n                      <jats:italic>n<\/jats:italic>\n                      = 353; complete-case\n                      <jats:italic>n<\/jats:italic>\n                      = 342). The prospective component was registered at the Chinese Clinical Trial Registry (ChiCTR2500099900).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the strict 434-case subset, NGS fungal-signal positivity was 81.3%, BALF-GM (\u22650.8) 58.1%, and culture 43.1%; pairwise overlap was substantial but incomplete. The GM-negative\/NGS-positive subgroup (\n                      <jats:italic>n<\/jats:italic>\n                      = 150) showed a milder phenotype than GM-positive\/NGS-positive cases (severe pneumonia 28.7% (43\/150) vs. 52.7% (107\/203); mortality 6.7% (10\/150) vs. 19.7% (40\/203); both\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). Severe pneumonia was independently inversely associated with GM-negative status (adjusted OR 0.44, 95% CI 0.26\u20130.75,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002), while immunocompromise was independently positively associated (adjusted OR 2.01, 95% CI 1.17\u20133.47,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.012). NGS Aspergillus positivity was essentially flat across BALF-GM intensity bands (79\u201382%); read counts correlated only weakly with BALF-GM titer [Spearman \u03c1 = 0.185 (mNGS-only,\n                      <jats:italic>n<\/jats:italic>\n                      = 246)].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>When BALF-GM and NGS are co-ordered on the same lavage in routine PAM workup, the four GM \u00d7 NGS quadrants define distinct clinical phenotypes with concrete management implications: NGS positivity in GM-negative cases (34.6%) carries the highest incremental yield and a milder phenotype; conversely, a negative NGS in GM-positive cases must not be used to rule out severe PAM. Across quadrants, NGS adds species- and co-pathogen-level information that changes therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1873197","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:22:15Z","timestamp":1784737335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Interpreting combined BALF-galactomannan and next-generation sequencing in pulmonary aspergillosis and mucormycosis: a two-center clinical decision framework"],"prefix":"10.3389","volume":"17","author":[{"given":"Lan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Harbin Medical University","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Second People\u2019s Hospital of Weifang","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, National Centre for Clinical Research on Respiratory Diseases, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, National Centre for Clinical Research on Respiratory Diseases, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ijid.2022.07.054","article-title":"Diagnostic performance of metagenomic next-generation sequencing for the detection of pathogens in bronchoalveolar lavage fluid in patients with pulmonary infections: Systematic review and meta-analysis.","volume":"122","author":"Chen","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"541092","DOI":"10.3389\/fcimb.2021.541092","article-title":"Application of metagenomic next-generation sequencing in the diagnosis of pulmonary infectious pathogens from bronchoalveolar lavage samples.","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium.","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jare.2021.09.012","article-title":"Metagenomics next-generation sequencing tests take the stage in the diagnosis of lower respiratory tract infections.","volume":"38","author":"Diao","year":"2021","journal-title":"J. Adv. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium.","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13054-015-0905-x","article-title":"Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients.","volume":"19","author":"Eigl","year":"2015","journal-title":"Crit. Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e23188","DOI":"10.1016\/j.heliyon.2023.e23188","article-title":"Metagenomic next generation sequencing of bronchoalveolar lavage samples for the diagnosis of lower respiratory tract infections: A systematic review and meta-analysis.","volume":"10","author":"Guo","year":"2024","journal-title":"Heliyon"},{"key":"B8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jinf.2018.05.001","article-title":"Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples.","volume":"77","author":"Heldt","year":"2018","journal-title":"J. Infect."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.3389\/fmicb.2018.01877","article-title":"Aspergillus PCR in bronchoalveolar lavage fluid for the diagnosis and prognosis of Aspergillosis in patients with hematological and non-hematological conditions.","volume":"9","author":"Imbert","year":"2018","journal-title":"Front. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s40121-021-00482-y","article-title":"Metagenomic next-generation sequencing for the diagnosis of Pneumocystis jirovecii pneumonia in non-HIV-infected patients: A retrospective study.","volume":"10","author":"Jiang","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance.","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.cmi.2021.02.005","article-title":"Serology anno 2021-fungal infections: from invasive to chronic.","volume":"27","author":"Lass-Fl\u00f6rl","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1093\/cid\/ciaa1786","article-title":"Defining galactomannan positivity in the updated EORTC\/MSGERC consensus definitions of invasive fungal diseases.","volume":"72","author":"Mercier","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11046-025-00996-w","article-title":"Sensitivity and specificity of polymerase chain reaction in blood and bronchoalveolar lavage samples for mucormycosis: A bayesian diagnostic test accuracy meta-analysis.","volume":"190","author":"Muthu","year":"2025","journal-title":"Mycopathologia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America.","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/mmy\/myx101","article-title":"Challenges in the diagnosis and treatment of mucormycosis.","volume":"56","author":"Skiada","year":"2018","journal-title":"Med. Mycol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"661589","DOI":"10.3389\/fcimb.2021.661589","article-title":"Metagenomic next-generation sequencing for pathogenic diagnosis and antibiotic management of severe community-acquired pneumonia in immunocompromised adults.","volume":"11","author":"Sun","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline.","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","article-title":"Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.","volume":"46","author":"Verweij","year":"2020","journal-title":"Intensive Care Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.chest.2024.07.144","article-title":"Effect of metagenomic next-generation sequencing on clinical outcomes of patients with severe community-acquired pneumonia in the ICU: A multicenter, randomized controlled trial.","volume":"167","author":"Wu","year":"2025","journal-title":"Chest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1220943","DOI":"10.3389\/fcimb.2023.1220943","article-title":"Metagenomic next-generation sequencing of bronchoalveolar lavage fluid assists in the diagnosis of pathogens associated with lower respiratory tract infections in children.","volume":"13","author":"Xu","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1873197\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:22:16Z","timestamp":1784737336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1873197\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":22,"alternative-id":["10.3389\/fmicb.2026.1873197"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1873197","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1873197"}}